Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma

BACKGROUND: Chemoradiation, followed by adjuvant temozolomide, is the standard treatment for newly diagnosed glioblastoma. Adding other active agents may enhance treatment efficacy. METHODS: The primary objective of this factorial phase II study was to determine if one of 3 potential chemotherapy ag...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Penas-Prado, Marta, Hess, Kenneth R., Fisch, Michael J., Lagrone, Lore W., Groves, Morris D., Levin, Victor A., De Groot, John F., Puduvalli, Vinay K., Colman, Howard, Volas-Redd, Gena, Giglio, Pierre, Conrad, Charles A., Salacz, Michael E., Floyd, Justin D., Loghin, Monica E., Hsu, Sigmund H., Gonzalez, Javier, Chang, Eric L., Woo, Shiao Y., Mahajan, Anita, Aldape, Kenneth D., Yung, W. K. Alfred, Gilbert, Mark R.
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2015
Assuntos:
Clinical Investigations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4288521/
https://ncbi.nlm.nih.gov/pubmed/25239666
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou155
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados